35 unknown. 35 Phase 2, 8 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Unknown 35 |
| Phase 1 | 8 | Unknown 8 |
| Phase 3 | 4 | Unknown 4 |
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biological Effects of Quercetin in COPD Phase II Quercetin 1000 mg, Quercetin 500 MG, Placebo - Chronic Obstructive Pulmonary Disease, Emphysema | Phase 2 | Unknown | Temple University | 30 | 2023-11-01 | 2024-04-08 |
| Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease Bronpass Tab., Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Unknown | Hanlim Pharm. Co., Ltd. | 96 | 2023-06-01 | 2024-05-30 |
| Immunological Basis for Mepolizumab Activity in COPD Mepolizumab 100 MG - COPD | Phase 2 | Unknown | Temple University | 30 | 2023-04-01 | 2023-04-07 |
| Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD) Benralizumab, Benralizumab placebo, Comparison (control) group; no intervention - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Unknown | Temple University | 45 | 2023-04-01 | 2023-04-07 |
| Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD Tezepelumab, Placebo - COPD, COPD Exacerbation | Phase 2 | Unknown | Asger Sverrild | 80 | 2022-10-25 | 2024-08-21 |
| Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases AntiSARS-CoV-2 Serum, Placebo - Immunosuppression, Cancer | Phase 1 / Phase 2 | Unknown | Butantan Institute | 618 | 2021-05-01 | 2021-04-08 |
| Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) Benralizumab, Prednisolone - Asthma, COPD | Phase 2 | Unknown | University of Oxford | 158 | 2021-03-29 | 2024-01-23 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD) placebo, Cavosonstat 5 mg, Cavosonstat 10 mg - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Unknown | GSNOR Therapeutics, Inc. | 108 | 2021-02-03 | 2020-10-23 |
| High Flow Nasal Cannula Oxygen During Sedation for Video-assisted Thoracoscopic Surgery High flow nasal cannula, CONTROL - Chronic Obstructive Pulmonary Disease, Respiratory Failure | Phase 2 | Unknown | Alexandria University | 60 | 2020-08-01 | 2020-08-20 |
| Biological Effects of Quercetin in COPD Quercetin - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Unknown | Temple University | 29 | 2019-10-01 | 2023-08-16 |
| Morphine to Maximize the Benefits of Exercise Training in COPD or ILD and Persistent Breathlessness Exercise training with morphine, Exercise training with placebo - Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease | Phase 2 | Unknown | Dennis Jensen, Ph.D. | 40 | 2019-08-06 | 2019-08-16 |
| Allogeneic MSC Treatment for Pulmonary Emphysema Allogeneic MSC, Placebo - Pulmonary Emphysema, Mesenchymal Stromal Cells | Phase 2 | Unknown | Leiden University Medical Center | 30 | 2019-06-25 | 2021-06-09 |
| Inhaled NO in IPF and COPD During 6 Minute Walk Test Inhaled nitric oxide - COPD, IPF | Phase 2 | Unknown | Rabin Medical Center | 100 | 2019-03-04 | 2019-12-26 |
| This Study Include Chronic Obstructive Pulmonary Disease(COPD) Patients . Patients Were Vitamin D Deficient Age Range 40 to 80 Years, Smokers Patients Were Advised to Take Either Placebo or Vitamin D3 . Antioxidant Enzymes Were Assessed at Baseline and at 26th Weeks. cholecalciferol, Placebo oral capsule - Chronic Obstructive Pulmonary Disease | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 40 | 2019-03-01 | 2019-07-09 |
| Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial Ferric Carboxymaltose, Sodium Chloride 0.9% - Chronic Obstructive Pulmonary Disease | Phase 2 | Unknown | Royal Brompton & Harefield NHS Foundation Trust | 40 | 2017-04-01 | 2017-05-12 |
| Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Bronchial basal cell - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 20 | 2017-03-01 | 2017-03-28 |
| CAN BREATHE in COPD Trial Cannabis, Placebo - Chronic Obstructive Pulmonary Disease (COPD), Breathlessness | Phase 2 | Unknown | McGill University | 16 | 2017-03-01 | 2017-02-23 |
| Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease Adipose derived stem cells - COPD | Phase 1 / Phase 2 | Unknown | University of Science Ho Chi Minh City | 20 | 2015-06-01 | 2016-01-01 |
| Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients Bone marrow harvesting, Liposuction - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | Unknown | UPECLIN HC FM Botucatu Unesp | 20 | 2015-04-01 | 2016-05-24 |
| A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota Fluticasone group, Budesonide group, Formoterol group - Chronic Obstructive Pulmonary Disease | Phase 2 | Unknown | University of British Columbia | 69 | 2015-02-01 | 2020-03-30 |
Showing 20 of 35. Sign in to see all of them.
Emphysema (4) · Dyspnea (3) · Asthma (2) · Diabetes Mellitus (2) · Inflammation (2) · Motor Activity (2) · Pulmonary Emphysema (2) · Airway Obstruction (1) · Blister (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Heart Failure (1) · Hypertension (1) · Immune System Diseases (1)
Chronic Disease (35) · Disease Attributes (35) · Lung Diseases (35) · Pathologic Processes (35) · Pathological Conditions, Signs and Symptoms (35) · Respiratory Tract Diseases (35) · Lung Diseases, Obstructive (34) · Respiration Disorders (5) · Signs and Symptoms (3) · Signs and Symptoms, Respiratory (3) · Behavior (2) · Bronchial Diseases (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Hypersensitivity (2)
Budesonide, Formoterol Fumarate Drug Combination (2) · Exercise (2) · Quercetin (2) · benralizumab (2) · Aspirin (1) · Bosentan (1) · Calcitriol (1) · Cholecalciferol (1) · Erythromycin (1) · Fluticasone-Salmeterol Drug Combination (1) · Formoterol Fumarate (1) · IMD-1041 (1) · Lipectomy (1) · Medicine, Chinese Traditional (1) · Morphine (1)
Temple University (4) · University of East Anglia (2) · Air Force Military Medical University, China (1) · Alexandria University (1) · Asger Sverrild (1) · Assaf-Harofeh Medical Center (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Butantan Institute (1) · C. T. Lamont Primary Care Research Centre (1) · CES University (1) · Chelsea and Westminster NHS Foundation Trust (1) · Dennis Jensen, Ph.D. (1) · GSNOR Therapeutics, Inc. (1) · Hanlim Pharm. Co., Ltd. (1) · Heidelberg University (1)
United Kingdom (8) · Canada (4) · Brazil (3) · China (2) · Israel (2) · United States (2) · Austria (1) · Bangladesh (1) · Denmark (1) · Egypt (1) · Germany (1) · Netherlands (1) · South Korea (1) · Sweden (1) · Taiwan (1)
Thomas Rogers, PhD (2) · Adelson Alves, Dr (1) · Andressa Forte (1) · Andrew Wilson, MD MRCP (UK) (1) · Andrew Wilson, MD, MRCP (UK) (1) · Asger Sverrild, MD, PhD (1) · Dennis Jensen, Ph.D (1) · Dennis Jensen, Ph.D. (1) · Dirceu Costa, PhD (1) · Don Sin, MD (1) · Ellie Fiss, MD (1) · Felix JF Herth, MD (1) · Jacques Lemelin, MD (1) · Jadwiga A Wedzicha, MD (1)
PMID 20920189, PMID 22465313, PMID 29975735, PMID 18723437, PMID 20008582, PMID 20090057, PMID 20154234, PMID 22459779, PMID 22799753, PMID 22893340, PMID 24271095, PMID 25762226, PMID 30049223, PMID 32071149, PMID 34464242, PMID 34610114, PMID 35740433, PMID 37546740, PMID 38468259, PMID 38536165, PMID 38724947, PMID 39615502
R33AT009991 (2), 2016 (1), 2018 (1)